




Instance: composition-en-56a32a5ee239fc834b47c10db1faa3fd
InstanceOf: CompositionUvEpi
Title: "Composition for flucelvax Package Leaflet"
Description:  "Composition for flucelvax Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf910e60e1f6c64b37237023544f44e6a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - flucelvax"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Flucelvax Tetra is and what it is used for  </li>
<li>What you need to know before you receive  Flucelvax Tetra  </li>
<li>How Flucelvax Tetra is given  </li>
<li>Possible side effects  </li>
<li>How to store Flucelvax Tetra   </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What flucelvax is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What flucelvax is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Flucelvax Tetra is a vaccine against flu (influenza). Flucelvax Tetra is prepared in cell cultures, and, 
therefore, is egg-free. 
When a person is given the vaccine, the immune system (the body s natural defence system) will 
produce its own protection against the influenza virus. None of the ingredients in the vaccine can 
cause flu. </p>
<p>Flucelvax Tetra is used to prevent flu in adults and children from 2 years of age. </p>
<p>The vaccine targets four strains of influenza virus following the recommendations by the World 
Health Organisation for the 2023/2024 SEASON. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take flucelvax"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take flucelvax"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You should not receive Flucelvax Tetra: 
If you are allergic to: 
* the active ingredients or any of the other ingredients of this medicine (listed in section 6) 
* beta-propiolactone, cetyltrimethylammonium bromide, or polysorbate 80, which are trace 
residues from the manufacturing process. </p>
<p>Warnings and precautions<br />
Talk to your doctor, pharmacist or nurse before receiving Flucelvax Tetra. </p>
<p>BEFORE receiving the vaccine 
* Your doctor or nurse will make sure that appropriate medical treatment and supervision is readily 
available in case of a rare anaphylactic reaction (a very severe allergic reaction with symptoms 
such as difficulty in breathing, dizziness, a weak and rapid pulse and skin rash) following the 
administration. This reaction may occur with Flucelvax Tetra as with all vaccines that are injected. 
* You should tell your doctor if you have an acute illness associated with fever. Your doctor may 
decide to delay your vaccination until your fever is gone. </p>
<ul>
<li>You should tell your doctor if your immune system is impaired, or if you are undergoing treatment 
which affects the immune system, e.g. with medicine against cancer (chemotherapy) or 
corticosteroid medicines (see section  Other medicines and Flucelvax Tetra ). </li>
<li>You should tell your doctor if you have a bleeding problem or bruise easily. </li>
<li>Fainting can occur following, or even before, any needle injection, therefore tell the doctor or 
nurse if you fainted with a previous injection. </li>
</ul>
<p>As with all vaccines, Flucelvax Tetra may not fully protect all persons who are vaccinated. </p>
<p>Children aged less than 2 years 
This vaccine is currently not recommended in children aged less than 2 years as safety and efficacy in 
this age group have not been established. </p>
<p>Other medicines and Flucelvax Tetra<br />
Tell your doctor or nurse if you are using, have recently used or might use any other medicines, 
including medicines obtained without a prescription or if you have recently received any other 
vaccine. </p>
<p>Flucelvax Tetra may be given at the same time as other vaccines. </p>
<p>Pregnancy and breast-feeding<br />
Pregnancy 
Tell your doctor if you are pregnant, think you may be pregnant or are planning to have a baby. 
Influenza vaccines may be given in any trimester of pregnancy.  </p>
<p>Breast-feeding 
Use of Flucelvax Tetra during breast-feeding has not been studied. No effects on breast fed babies are 
expected. Flucelvax Tetra may be given during breast-feeding. </p>
<p>Driving and using machines 
Flucelvax Tetra has no or negligible effect on your ability to drive and use machines. </p>
<p>Flucelvax Tetra contains sodium chloride and potassium chloride 
This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 
 sodium-free . 
This vaccine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially  potassium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take flucelvax"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take flucelvax"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Flucelvax Tetra is given to you by your doctor or nurse as an injection into the muscle at the top of the 
upper arm (deltoid muscle) or into the muscle of the upper and outer part of the thigh in young 
children depending on the muscle size. </p>
<p>Adults and children from 2 years of age: </p>
<p>One dose of 0.5 ml </p>
<p>If your child is younger than 9 years of age and has not been previously vaccinated against flu, a 
second dose should be given after at least 4 weeks. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. 
The following side effects have been reported during clinical studies and during general use: </p>
<p>Very serious side effects 
Tell your doctor immediately or go to the casualty department at your nearest hospital if you 
experience the following side effect   you may need urgent medical attention or hospitalisation: </p>
<p>Difficulty in breathing, dizziness, a weak and rapid pulse and skin rash which are symptoms of an 
anaphylactic reaction (a very severe allergic reaction) </p>
<p>Serious side effects 
Tell your doctor immediately if you experience any of the following side effects   you may need 
medical attention: </p>
<p>You feel weak, you have difficulty moving around or you experience numbness or tingling in your 
limbs. These can be symptoms of  Guillain-Barr  syndrome (GBS), an autoimmune disease caused 
by your body s own immune system. 
  Extensive swelling of injected limb </p>
<p>Other side effects 
Very common (may affect more than 1 in 10 people) 
  Injection site pain, bruising, reddening and hardening or swelling at the site of the injection 
  Headache 
  Muscle pain <br />
  Tiredness<br />
  Loss of appetite 
  Irritability (only reported in children from 2 to &lt; 6 years) 
  Sleepiness (only reported in children 2 to &lt; 6 years) 
Hardening or swelling at the site of the injection, headache, muscle pain, and tiredness were common 
in the elderly. 
Bruising at the site of the injection was common in adults, eldery and children 9 to &lt; 18 years. 
Headache was common in the elderly. 
Loss of appetite was common in adults, eldery and children 9 to &lt; 18 years. </p>
<p>Common (may affect up to 1 in 10 people) 
  Nausea, vomiting, diarrhoea<br />
  Joint pain 
  Shivering 
  Change in eating habits (only reported in children from 2 to &lt; 6 years) 
  Fever (&gt; 38 C) 
Vomiting was uncommon in the elderly. 
Fever was uncommon in adults and the elderly. </p>
<p>Not known (frequency cannot be estimated from the available data) 
  Numbness and tingling sensation (paraesthesia) 
  Generalised skin reactions including itching, bumps on the skin (pruritis, urticaria) or non-specific 
rash  </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects, you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store flucelvax"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store flucelvax"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this vaccine out of the sight and reach of children. </p>
<p>Do not use this vaccine after the expiry date which is stated on the label and carton after EXP. The 
expiry date refers to the last day of that month. </p>
<p>Store in a refrigerator (2  C to 8  C). Do not freeze. 
Keep the pre-filled syringe in the outer carton in order to protect from light. </p>
<p>. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Flucelvax Tetra contains  </p>
<p>The active substances are influenza virus surface antigens (haemagglutinin and neuraminidase), 
inactivated, of the following strains*: </p>
<p>A/Wisconsin/67/2022 (H1N1)pdm09-like strain (A/Georgia/12/2022 CVR-167) 15 micrograms HA<strong> 
A/Darwin/6/2021 (H3N2)-like strain (A/Darwin/11/2021, wild type) 15 micrograms HA</strong> 
B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021, wild type) 15 micrograms HA<strong> 
B/Phuket/3073/2013-like strain (B/Singapore/INFTT-16-0610/2016, wild type) 15 micrograms HA</strong> </p>
<p>per 0.5 ml dose 
 . 
* 
propagated in Madin Darby Canine Kidney (MDCK) cells (this is the special cell culture in 
which the influenza virus is grown);<br />
** 
haemagglutinin </p>
<p>This vaccine complies with the World Health Organisation (WHO) recommendation (northern 
hemisphere) and EU recommendation for the 2023/2024 SEASON. </p>
<p>The other ingredients are: sodium chloride, potassium chloride, magnesium chloride hexahydrate, 
disodium phosphate dihydrate, potassium dihydrogen phosphate and water for injections. 
(see Section 2   Flucelvax Tetra contains sodium and potassium) </p>
<p>What Flucelvax Tetra looks like and contents of the pack </p>
<p>Flucelvax Tetra is a suspension for injection (injection) in a pre-filled syringe (ready to use syringe).<br />
Flucelvax Tetra is a clear to slightly opalescent suspension. 
A single syringe contains 0.5 ml of suspension for injection. 
Flucelvax Tetra is available in packs containing 1 pre-filled syringe with or without needle or 10 pre-
filled syringes with or without needles. 
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Seqirus Netherlands B.V. 
Paasheuvelweg 1105BJ Amsterdam 
Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Lietuva </p>
<p>Seqirus Netherlands B.V.Nederland/Netherlands 
Tel: +31 (0) 20 204 6<br />
Seqirus Netherlands B.V. <br />
 .: +31 (0) 20 204 6 esk  republika 
Seqirus Netherlands B.V. Nizozemsko 
Tel: +31 (0) 20 204 6Danmark 
Seqirus Netherlands B.V. Holland 
Tlf: +31 (0) 20 204 6Deutschland 
Seqirus GmbH Marburg 
Tel: 08003601Eesti 
Seqirus Netherlands B.V. Holland 
Tel: +31 (0) 20 204 6<br />
WIN MEDICA  . . 
 : 210 7488Espa a 
Seqirus Spain, S.L., Barcelona 
Tel: 937 817 France 
Seqirus Netherlands B.V. Netherlands 
T l: +31 (0) 20 204 6Hrvatska 
Seqirus Netherlands B.V. Nizozemska 
Tel: +31 (0) 20 204 6Ireland 
Seqirus UK Limited Maidenhead 
Tel: +44 1628 641  sland 
Seqirus Netherlands B.V. Holland 
S mi: +31 (0) 20 204 6Italia 
Seqirus S.r.l. Siena 
Tel: +39 0577 096<br />
Seqirus Netherlands B.V. <br />
 : +31 (0) 20 204 6Latvija 
Seqirus Netherlands B.V. Nyderlandai 
Tel: +31 (0) 20 204 6Luxembourg/Luxemburg 
Seqirus Netherlands B.V. Netherlands 
T l/Tel: +31 (0) 20 204 6Magyarorsz g 
Seqirus Netherlands B.V. Hollandia 
Tel.: +31 (0) 20 204 6Malta 
Seqirus Netherlands B.V. In-Netherlands 
Tel: +31 (0) 20 204 6Nederland 
Seqirus Netherlands B.V. Amsterdam 
Tel: +31 (0) 20 204 6Norge 
Seqirus Netherlands B.V. Nederland 
Tlf: +31 (0) 20 204 6 sterreich 
Valneva Austria GmbH, Wien 
Tel: +43 1 20620 2Polska 
Seqirus Netherlands B.V. Holandia 
Tel.: +31 (0) 20 204 6Portugal 
Seqirus Netherlands B.V. Pa ses Baixos 
Tel: +31 (0) 20 204 6Rom nia 
Seqirus Netherlands B.V. Olanda 
Tel: +31 (0) 20 204 6Slovenija 
Seqirus Netherlands B.V. Nizozemska 
Tel: +31 (0) 20 204 6Slovensk  republika 
Seqirus Netherlands B.V. Holandsko 
Tel: +31 (0) 20 204 6Suomi/Finland 
Seqirus Netherlands B.V. Alankomaat 
Puh/Tel: +31 (0) 20 204 6Sverige 
Seqirus Netherlands B.V. Nederl nderna 
Tel: +31 (0) 20 204 6Seqirus Netherlands B.V. N derlande 
Tel: +31 (0) 20 204 6This leaflet was last revised in. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-56a32a5ee239fc834b47c10db1faa3fd
InstanceOf: CompositionUvEpi
Title: "Composition for flucelvax Package Leaflet"
Description:  "Composition for flucelvax Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf910e60e1f6c64b37237023544f44e6a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - flucelvax"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du får Flucelvax Tetra </li>
<li>Sådan gives Flucelvax Tetra </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What flucelvax is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What flucelvax is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Flucelvax Tetra er en vaccine mod influenza. Flucelvax Tetra fremstilles i cellekulturer og er derfor fri 
for æg. 
Når en person får vaccinen, vil immunsystemet (kroppens naturlige forsvarssystem) danne sin egen 
beskyttelse mod influenzavirus. Ingen af indholdsstofferne i vaccinen kan forårsage influenza. </p>
<p>Flucelvax Tetra anvendes til at forebygge influenza hos voksne og børn fra 2 år. </p>
<p>Vaccinen er rettet mod fire influenzavirusstammer efter Verdenssundhedsorganisationens (WHO’s) 
anbefalinger for SÆSONEN 2023/2024. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take flucelvax"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take flucelvax"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du bør ikke få Flucelvax Tetra: 
Hvis du er allergisk over for: </p>
<ul>
<li>
<p>de aktive stoffer eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet i punkt 6) </p>
</li>
<li>
<p>beta-propiolacton, cetyltrimethylammoniumbromid eller polysorbat 80, som er sporrester fra 
fremstillingsprocessen. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du får Flucelvax Tetra. </p>
<p>FØR du får vaccinen </p>
<ul>
<li>
<p>Din læge eller sygeplejerske sørger for, at du kan få den rette behandling og overvågning i 
tilfælde af, at vaccinen skulle fremkalde en voldsom allergisk reaktion (anafylaktisk reaktion, 
med symptomer som vejrtrækningsbesvær, svimmelhed, svag og hurtig puls og udslæt). 
Sådanne reaktioner opstår dog kun sjældent, men de kan forekomme med Flucelvax Tetra 
ligesom med alle andre vacciner, der indsprøjtes. </p>
</li>
<li>
<p>Du skal fortælle det til lægen, hvis du har en akut sygdom, der er forbundet med feber. Lægen 
kan beslutte at udsætte din vaccination, til feberen har fortaget sig. 
9 </p>
</li>
<li>
<p>Du skal fortælle det til lægen, hvis dit immunforsvar er nedsat, eller hvis du er i behandling, 
som påvirker immunforsvaret, f.eks. med lægemidler mod kræft (kemoterapi) eller lægemidler, 
der indeholder kortikosteroid (se punktet "Brug af andre lægemidler sammen med 
Flucelvax Tetra").  </p>
</li>
<li>
<p>Du skal fortælle det til lægen, hvis du har et blødningsproblem eller let får blå mærker. </p>
</li>
<li>
<p>Der kan forekomme besvimmelse efter eller endog før en kanyleinjektion. Du skal derfor 
fortælle det til lægen eller sygeplejersken, hvis du er besvimet ved en tidligere indsprøjtning. </p>
</li>
</ul>
<p>Som det gælder for alle vacciner, giver Flucelvax Tetra muligvis ikke fuldstændig beskyttelse for alle 
personer, der vaccineres. </p>
<p>Børn under 2 år 
Denne vaccine er aktuelt ikke anbefalet til børn under 2 år, da sikkerhed og virkning hos denne 
aldersgruppe ikke er klarlagt. </p>
<p>Brug af andre lægemidler sammen med Flucelvax Tetra 
Fortæl altid lægen eller sygeplejersken, hvis du bruger andre lægemidler, for nylig har brugt andre 
lægemidler eller planlægger at bruge andre lægemidler. Det gælder også lægemidler, som ikke er købt 
på recept, eller hvis du har fået en anden vaccine for nylig. </p>
<p>Flucelvax Tetra kan gives samtidig med andre vacciner.  </p>
<p>Graviditet og amning 
Graviditet 
Fortæl det til lægen, hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive 
gravid. Influenzavacciner kan gives i alle trimestre af graviditeten. </p>
<p>Amning 
Anvendelse af Flucelvax Tetra under amning er ikke blevet undersøgt. Der forventes ingen virkning 
på ammede børn. Flucelvax Tetra kan gives under amning. </p>
<p>Trafik- og arbejdssikkerhed 
Flucelvax Tetra påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene 
maskiner. </p>
<p>Flucelvax Tetra indeholder natriumchlorid og kaliumchlorid 
Denne vaccine indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, dvs. den er i det væsentlige 
natriumfri. 
Denne vaccine indeholder mindre end 1 mmol (39 mg) kalium pr. dosis, dvs. den er i det væsentlige 
kaliumfri. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take flucelvax"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take flucelvax"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Flucelvax Tetra gives af lægen eller sygeplejersken som en indsprøjtning i musklen øverst på 
overarmen (deltamusklen) eller i musklen på den øvre og ydre del af låret hos små børn, afhængig af 
musklens størrelse. </p>
<p>Voksne og børn fra 2 år: </p>
<p>Én dosis på 0,5 ml. </p>
<p>Hvis dit barn er under 9 år gammelt og ikke tidligere er blevet vaccineret mod influenza, bør der gives 
en dosis nummer 2 efter mindst 4 uger. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Følgende bivirkninger er blevet rapporteret under kliniske studier og almindelig brug: </p>
<p>Meget alvorlige bivirkninger 
Søg omgående læge eller tag på skadestuen på det nærmeste hospital, hvis du får følgende bivirkning - 
du kan have brug for akut lægehjælp eller indlæggelse: </p>
<ul>
<li>Vejrtrækningsbesvær, svimmelhed, en svag og hurtig puls og udslæt, hvilket er symptomer på 
en meget alvorlig allergisk reaktion (anafylaktisk reaktion) </li>
</ul>
<p>Alvorlige bivirkninger 
Søg omgående læge, hvis du får en eller flere af følgende bivirkninger - du kan have brug for 
lægehjælp: </p>
<ul>
<li>
<p>Du føler dig svag, du har svært ved at bevæge dig omkring, eller du oplever følelsesløshed og 
en snurrende fornemmelse i dine arme og ben. Det kan være symptomer på Guillain-Barré 
syndrom (GBS), en autoimmun sygdom, der forårsages af kroppens eget immunsystem. </p>
</li>
<li>
<p>Kraftig hævelse af injiceret arm </p>
</li>
</ul>
<p>Andre bivirkninger 
Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer) 
• Smerter, blåfarvning, rødme og hårdhed eller hævelse på injektionsstedet 
• Hovedpine 
• Muskelsmerter<br />
• Træthed 
• Appetitløshed 
• Irritabilitet (kun rapporteret hos børn på 2 til under 6 år) 
• Søvnighed (kun rapporteret hos børn på 2 til under 6 år) 
Hårdhed eller hævelse på injektionsstedet, hovedpine, muskelsmerter og træthed var almindelige hos 
ældre. 
Blåfarvning på injektionsstedet var almindelig hos voksne, ældre og børn på 9 til under 18 år. 
Hovedpine var almindelig hos ældre. 
Appetitløshed var almindelig hos voksne, ældre og børn på 9 til under 18 år. </p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer) 
• Kvalme, opkastning, diarré 
• Ledsmerter 
• Kulderystelser 
• Ændrede spisevaner (kun rapporteret hos børn på 2 til under 6 år) 
• Feber (over 38 °C)<br />
Opkastning var ikke almindelig hos ældre.<br />
Feber var ikke almindelig hos voksne og ældre. </p>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data) 
• Følelsesløshed og snurrende fornemmelse (paræstesi) 
• Udbredte hudreaktioner, herunder kløe, knopper på huden (pruritus, urticaria) eller ikke-specifikt 
udslæt </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store flucelvax"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store flucelvax"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar vaccinen utilgængeligt for børn. </p>
<p>Brug ikke vaccinen efter den udløbsdato, der står på etiketten og på æsken efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2 °C til 8 °C).Må ikke nedfryses. </p>
<p>Opbevar den fyldte injektionssprøjte i den ydre æske for at beskytte mod lys. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Flucelvax Tetra indeholder </p>
<ul>
<li>Aktive stoffer: Influenzavirus-overfladeantigener (hæmagglutinin og neuraminidase), 
inaktiverede, fra følgende stammer*: </li>
</ul>
<p>A/Wisconsin/67/2022 (H1N1)pdm09-lignende stamme (A/Georgia/12/2022 CVR-167) 
15 mikrogram HA<strong> 
A/Darwin/6/2021 (H3N2)-lignende stamme (A/Darwin/11/2021, vildtype) 15 mikrogram HA</strong> 
B/Austria/1359417/2021-lignende stamme (B/Singapore/WUH4618/2021, vildtype) 
15 mikrogram HA<strong> 
B/Phuket/3073/2013-lignende stamme (B/Singapore/INFTT-16-0610/2016, vildtype) 
15 mikrogram HA</strong> </p>
<p>pr. 0,5 ml-dosis 
………………………………………. </p>
<ul>
<li>opformeret i Madin Darby Canine Kidney (MDCK)-celler (dette er den specielle cellekultur, 
hvori influenzavirus er dyrket) </li>
</ul>
<p>** 
hæmagglutinin </p>
<p>Vaccinen opfylder Verdensundhedsorganisationen (WHO’s) anbefalinger for den nordlige halvkugle 
samt EU’s bestemmelser for SÆSONEN 2023/2024. - Øvrige indholdsstoffer: natriumchlorid, kaliumchlorid, magnesiumchloridhexahydrat, 
dinatriumphosphatdihydrat, kaliumdihydrogenphosphat og vand til injektionsvæsker (se punkt 2 
- Flucelvax Tetra indeholder natrium og kalium). </p>
<p>Udseende og pakningsstørrelser </p>
<p>Flucelvax Tetra er en injektionsvæske, suspension (injektion) i en fyldt injektionssprøjte (brugsklar 
sprøjte).<br />
Flucelvax Tetra er en klar til let opaliserende suspension. 
En enkelt sprøjte indeholder 0,5 ml injektionsvæske, suspension. 
Flucelvax Tetra findes i pakninger, der indeholder 1 fyldt injektionssprøjte med eller uden kanyle eller 
10 fyldte injektionssprøjter med eller uden kanyler.<br />
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Seqirus Netherlands B.V. 
Paasheuvelweg 1105BJ Amsterdam 
Holland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Seqirus Netherlands B.V. 
Nederland/Netherlands 
Tel: +31 (0) 20 204 6 
България 
Seqirus Netherlands B.V. Нидерландия 
Тел.: +31 (0) 20 204 6 
Česká republika 
Seqirus Netherlands B.V. Nizozemsko 
Tel: +31 (0) 20 204 6 
Danmark 
Seqirus Netherlands B.V. Holland 
Tlf: +31 (0) 20 204 6 
Deutschland 
Seqirus GmbH Marburg 
Tel: 0800/3601 
Eesti 
Seqirus Netherlands B.V. Holland 
Tel: +31 (0) 20 204 6 
Ελλάδα 
WIN MEDICA Α.Ε. 
Τηλ: 210 7488 
España 
Seqirus Spain, S.L., Barcelona 
Tel: 937 817<br />
France 
Seqirus Netherlands B.V. Netherlands 
Tél: +31 (0) 20 204 6 
Hrvatska 
Seqirus Netherlands B.V. Nizozemska 
Tel: +31 (0) 20 204 6 
Ireland 
Seqirus UK Limited Maidenhead 
Tel: +44 1628 641<br />
Ísland 
Seqirus Netherlands B.V. Holland 
Lietuva 
Seqirus Netherlands B.V. Nyderlandai 
Tel: +31 (0) 20 204 6 </p>
<p>Luxembourg/Luxemburg 
Seqirus Netherlands B.V. Netherlands 
Tél/Tel: +31 (0) 20 204 6 
Magyarország 
Seqirus Netherlands B.V. Hollandia 
Tel.: +31 (0) 20 204 6 
Malta 
Seqirus Netherlands B.V. In-Netherlands 
Tel: +31 (0) 20 204 6 
Nederland 
Seqirus Netherlands B.V. Amsterdam 
Tel: +31 (0) 20 204 6 
Norge 
Seqirus Netherlands B.V. Nederland 
Tlf: +31 (0) 20 204 6 
Österreich 
Valneva Austria GmbH, Wien 
Tel: +43 1 20620 2 
Polska 
Seqirus Netherlands B.V. Holandia 
Tel.: +31 (0) 20 204 6 
Portugal 
Seqirus Netherlands B.V. Países Baixos 
Tel: +31 (0) 20 204 6 
România 
Seqirus Netherlands B.V. Olanda 
Tel: +31 (0) 20 204 6 
Slovenija 
Seqirus Netherlands B.V. Nizozemska 
Tel: +31 (0) 20 204 6 
Slovenská republika 
Seqirus Netherlands B.V. Holandsko 
Sími: +31 (0) 20 204 6 
Italia 
Seqirus S.r.l. Siena 
Tel: +39 0577 096 
Κύπρος 
Seqirus Netherlands B.V. Ολλανδία 
Τηλ: +31 (0) 20 204 6 
Latvija 
Seqirus Netherlands B.V. Nīderlande 
Tel: +31 (0) 20 204 6 
Tel: +31 (0) 20 204 6 
Suomi/Finland 
Seqirus Netherlands B.V. Alankomaat 
Puh/Tel: +31 (0) 20 204 6 
Sverige 
Seqirus Netherlands B.V. Nederländerna 
Tel: +31 (0) 20 204 6 </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>
<p>------------------------------------------------------------------------------------------------------------------------ Nedenstående oplysninger er til læger og sundhedspersonale: </p>
<p>Passende medicinsk behandling samt overvågning skal altid være let tilgængelig i tilfælde af en 
sjælden anafylaktisk reaktion efter administration af vaccinen. </p>
<p>Omrystes før brug. Efter omrystning fremstår vaccinen normalt som en klar til let opaliserende 
suspension. </p>
<p>Vaccinen skal inspiceres visuelt for partikler og misfarvning før administration. Vaccinen må ikke 
administreres, hvis der observeres urenheder i form af partikler og/eller variation i fysisk 
beskaffenhed. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-56a32a5ee239fc834b47c10db1faa3fd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for flucelvax Package Leaflet for language en"
Description: "ePI document Bundle for flucelvax Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-56a32a5ee239fc834b47c10db1faa3fd"
* entry[0].resource = composition-en-56a32a5ee239fc834b47c10db1faa3fd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp56a32a5ee239fc834b47c10db1faa3fd"
* entry[=].resource = mp56a32a5ee239fc834b47c10db1faa3fd
                            
                    
Instance: bundlepackageleaflet-da-56a32a5ee239fc834b47c10db1faa3fd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for flucelvax Package Leaflet for language da"
Description: "ePI document Bundle for flucelvax Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-56a32a5ee239fc834b47c10db1faa3fd"
* entry[0].resource = composition-da-56a32a5ee239fc834b47c10db1faa3fd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp56a32a5ee239fc834b47c10db1faa3fd"
* entry[=].resource = mp56a32a5ee239fc834b47c10db1faa3fd
                            
                    



Instance: mp56a32a5ee239fc834b47c10db1faa3fd
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product flucelvax"
Description: "flucelvax"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/18/1326/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Prophylaxis of influenza in adults and children from 2 years of age."


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "flucelvax"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 56a32a5ee239fc834b47c10db1faa3fdListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "flucelvax"

* status = #current
* mode = #working

* title = "List of all ePIs associated with flucelvax"

* subject = Reference(mpf910e60e1f6c64b37237023544f44e6a)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#flucelvax "flucelvax"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-56a32a5ee239fc834b47c10db1faa3fd) // flucelvax en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-56a32a5ee239fc834b47c10db1faa3fd) // flucelvax da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-56a32a5ee239fc834b47c10db1faa3fd
InstanceOf: List

* insert 56a32a5ee239fc834b47c10db1faa3fdListRuleset
    